RSOCs are akin to occupancy frequency distributions, but do not require binning species by frequency, and relate to ranked species abundance distributions [ 43, 44] but employ presence-absence data rather than abundance data.
This may be simply due to the absence of data rather than to biological reasons since there are genes conferring enhanced resistance to all combinations of two of these pathogens.
Due to limited EST and genomic data for these species, we currently assume this absence is due to a lack of sequence data, rather than gene loss.
Rather than relying on both presence and absence data points, Maxent uses presence-only data.
Many factors contribute to uncertainty regarding these findings, including availability of only summary trial-level data rather than patient-level data, heterogeneity of trial design, and absence of uniform event adjudication (9).
At present, it is mostly likely that the apparent absence of DIA1R in P. promelas, and DIA1 in I. punctatus, is due to limitations in EST data, rather than because of gene loss.
MaxEnt uses presence-only data rather than presence/absence data and has been shown to be a high-performing model-building program (20 ) and excels in using small numbers of occurrence points (21 ).
We chose logistic regression, rather than Poisson regression (i.e. analyzing the incidence rate of absence spells) because most employees had only 0 or 1 long-term absence each year, and the method was not influenced by high zero-inflation and over-dispersion in the sickness absence data.
What is significant from the Haiti experience is that there was not an absence of data, but rather an abundance of it, collected in different formats, on different platforms, using different indicators, and with varying degrees of comprehensiveness.
We argue that the conflicting results observed in the case of birds reflect the poor estimation of d N/d S in mitochondrial data sets, rather than an absence of relationship between body mass and the efficacy of selection in birds.
A guiding principle of treatment of metastatic disease is to respect the palliative goal of this therapy given the absence of data demonstrating superior survival benefit with combination cytotoxics rather than sequential strategies.
